LTR Pharma Limited (ASX:LTP)
Australia · Delayed Price · Currency is AUD 0.5200
+0.0250 (5.05%)
At close: Feb 18, 2026
LTR Pharma Revenue
In the fiscal year ending June 30, 2025, LTR Pharma had annual revenue of 1.51M AUD with 2,978.25% growth. LTR Pharma had revenue of 1.06M in the half year ending June 30, 2025.
Revenue
1.51M
Revenue Growth
+2,978.25%
P/S Ratio
62.67
Revenue / Employee
n/a
Employees
n/a
Market Cap
94.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.51M | 1.46M | 2,978.25% |
| Jun 30, 2024 | 49.00K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 9.08K | - | - |
| Jun 30, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 66.87M |
| Radiopharm Theranostics | 12.51M |
| Alterity Therapeutics | 5.44M |
| Imugene | 4.40M |
| Prescient Therapeutics | 4.36M |
| Arovella Therapeutics | 3.44M |
| Proteomics International Laboratories | 3.31M |
| Cynata Therapeutics | 1.89M |